Method for purifying nucleotide compounds

The combination of weak anion exchange column chromatography and saturated sodium iodide solution has solved the problems of low efficiency and high cost of batch purification of nucleotide compounds in the prior art, and achieved high efficiency and low cost high-purity nucleotides Compound production.

CN119080857APending Publication Date: 2024-12-06SHENZHEN ARCHEAN-TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411193353.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing purification methods of nucleotide compounds are not suitable for products ranging from 100 grams to kg. The production cycle is long and the cost is high. In particular, the reverse phase column chromatography method consumes a large amount of solvents and equipment and is difficult to achieve high purity and high efficiency. Batch purification.

Method used

The crystalline nucleotide sodium salt was precipitated by weak anion exchange column chromatography purification method and mixed with a saturated sodium iodide solution to improve the purity by regulating the crystallization conditions, achieving efficient purification of nucleotide compounds to reach ≥99%, and Shorten the production cycle.

Benefits of technology

The purification of nucleotide compounds with high purity is achieved, shortening the production cycle to 4 days, reducing production costs, and avoiding the high consumption of reverse phase column chromatography and the use of expensive equipment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005015684420000041
    Figure BDA0005015684420000041
  • Figure BDA0005015684420000042
    Figure BDA0005015684420000042
  • Figure BDA0005015684420000043
    Figure BDA0005015684420000043
Patent Text Reader

Abstract

The invention provides a purification method of a nucleotide compound, which comprises the following steps: purifying a nucleotide crude product through weak anion exchange column chromatography, and mixing with a sodium iodide saturated solution to separate out crystals to obtain a pure product. According to the purification method of the nucleotide compound, the purification treatment capacity of a single batch can be improved, high purity is achieved, the purification time is short, and the production cycle of the product is effectively shortened.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of nucleotides, and in particular relates to a method for purifying nucleotide compounds. Background Art

[0002] Nucleotides are a class of compounds composed of purine or pyrimidine bases, ribose or deoxyribose, and phosphate groups. Nucleotide compounds are widely used in the food, pharmaceutical, and agricultural industries, and the market demand for various nucleotide products is huge.

[0003] At present, the general method of production and purification of chemically synthesized nucleotides is to first elute and purify with ion exchange resin, then purify with reverse phase column chromatography, and finally obtain the product by concentration or nanofiltration. The purity of the product can reach 95% to 99%. However, this method of purifying nucleotide compounds is more suitable for the preparation of products in the milligram to gram range, but not for the purification of products in the hundred gram to kilogram range. Moreover, the consumption of solvent for preparation and purification by reverse phase is huge, and the sample loading amount of reverse phase column is small. The filler and high-pressure pump equipment are expensive. The volume of the collected product fraction after purification is large, and the product needs to be concentrated and freeze-dried to obtain the product. The production cycle is long and the cost is high.

[0004] Therefore, it is necessary to develop a method for purifying nucleotide compounds that can effectively purify nucleotide compounds, is time-saving and low-cost. Summary of the invention

[0005] In view of the deficiencies in the prior art, the object of the present invention is to provide a method for purifying nucleotide compounds, which can increase the purification processing capacity of a single batch of nucleotide compounds, achieve higher purity, shorten the purification time, and effectively shorten the production cycle of the product.

[0006] To achieve this object, the present invention adopts the following technical solutions:

[0007] The invention provides a method for purifying nucleotide compounds, which comprises the following steps: purifying a crude nucleotide product by weak anion exchange column chromatography, mixing the crude nucleotide product with a saturated sodium iodide solution to precipitate crystals, and obtaining a pure product.

[0008] In the present invention, the crude nucleotide is purified by weak anion exchange column chromatography, and mixed with a saturated sodium iodide solution to precipitate a crystalline sodium nucleotide salt, which can achieve effective purification to obtain a pure product. For example, the crude nucleotide includes a crude deoxyribonucleoside triphosphate, a crude dideoxyribonucleoside triphosphate, or a crude azide-containing deoxyribonucleoside triphosphate. The purification method of nucleotide compounds can increase the purification processing capacity of a single batch, achieve a higher purity, and can achieve a target purity of ≥99%, with a short purification time, which effectively shortens the production cycle of the product.

[0009] Preferably, the weak anion exchange column chromatography purification further includes a concentration step.

[0010] Preferably, the filler of the weak anion exchange column is DEAE filler.

[0011] Preferably, the mobile phase for the weak anion exchange column chromatography purification comprises mobile phase A and mobile phase B, the mobile phase A is pure water, and the mobile phase B is a triethylammonium carbonate aqueous solution.

[0012] Preferably, the concentration of the triethylammonium carbonate aqueous solution is 0.5-2 mol / L, for example, 0.7 mol / L, 0.9 mol / L, 1.1 mol / L, 1.3 mol / L, 1.5 mol / L, 1.7 mol / L or 1.9 mol / L.

[0013] Preferably, the pH of the triethylammonium carbonate aqueous solution is 7 to 8, for example, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8 or 7.9.

[0014] Preferably, the elution mode of the weak anion exchange column chromatography purification is gradient elution with a flow rate of 40 to 120 mL / min, for example, 50 mL / min, 60 mL / min, 70 mL / min, 80 mL / min, 90 mL / min, 100 mL / min or 110 mL / min.

[0015] Preferably, the solvent of the saturated sodium iodide solution is acetone.

[0016] In the present invention, the saturated sodium iodide solution refers to a saturated sodium iodide solution under the conditions of 10-35° C. and 101.325 kPa.

[0017] Preferably, the temperature of the precipitated crystals is 10-35°C, for example, 13°C, 16°C, 19°C, 22°C, 25°C, 28°C, 31°C or 34°C.

[0018] Preferably, the mixing further comprises mixing with ethanol or acetonitrile.

[0019] Preferably, based on the total mass of the saturated sodium iodide solution and ethanol or acetonitrile as 100%, the mass percentage of the saturated sodium iodide solution is 90% to 100% (for example, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, etc.), and the mass percentage of ethanol or acetonitrile is 0 to 10% (for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8% or 9%, etc.).

[0020] In the present invention, based on the total mass of the saturated sodium iodide solution and ethanol or acetonitrile as 100%, the mass percentage of the saturated sodium iodide solution is preferably 90% to 100%. If the mass percentage of the saturated sodium iodide solution is too low, crystallization is incomplete and the purification yield is reduced.

[0021] In the present invention, the purity of purification can be improved by regulating the crystallization conditions, thereby achieving the purpose of purifying nucleotide compounds.

[0022] Preferably, the process further comprises filtering and washing with acetone after the crystals are precipitated.

[0023] Preferably, the method for purifying nucleotide compounds specifically comprises the following steps: purifying the crude nucleotide by weak anion exchange column chromatography, concentrating, mixing with a saturated sodium iodide solution and optionally ethanol or acetonitrile to precipitate crystals, filtering, and washing with acetone to obtain a pure product.

[0024] The filler of the weak anion exchange column is DEAE filler, the mobile phase of the weak anion exchange column chromatography purification includes mobile phase A and mobile phase B, the mobile phase A is pure water, the mobile phase B is a triethylammonium carbonate aqueous solution with a concentration of 0.5 to 2 mol / L, and the elution mode of the weak anion exchange column chromatography purification is gradient elution with a flow rate of 40 to 120 mL / min.

[0025] Taking the total mass of the sodium iodide saturated solution and ethanol or acetonitrile as 100%, the mass percentage of the sodium iodide saturated solution is 90% to 100%, and the mass percentage of the ethanol or acetonitrile is 0 to 10%.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] The present invention purifies the crude nucleotide product by weak anion exchange column chromatography, and mixes it with a saturated sodium iodide solution to precipitate crystalline nucleotide sodium salt, which can achieve effective purification to obtain a pure product. The purification method of nucleotide compounds can increase the purification processing capacity of a single batch, achieve a higher purity, and can achieve a target purity of ≥99%. The purification time is short, and the production cycle of the product is effectively shortened to 4 days. DETAILED DESCRIPTION

[0028] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0029] The sources of some components in the preparation examples are as follows:

[0030] Nucleoside: Cold dC-N3, having the structure shown in Formula 1, purchased from Shenzhen Tanmi Technology Co., Ltd.;

[0031]

[0032] Nucleoside: Cold dT-N3, having the structure shown in Formula 2, purchased from Shenzhen Tanmi Technology Co., Ltd.;

[0033]

[0034] Nucleoside: Cold dA-N3, having the structure shown in Formula 3, purchased from Shenzhen Tanmi Technology Co., Ltd.;

[0035]

[0036] Nucleoside: Cold dG-N3, having the structure shown in Formula 4, purchased from Shenzhen Tanmi Technology Co., Ltd.;

[0037]

[0038] Preparation Example 1

[0039] This preparation example provides a crude nucleotide product, specifically a deoxyribonucleoside triphosphate reaction solution dNTP-1, and the preparation method thereof is as follows:

[0040] Pretreatment: Dry a 1000mL three-necked bottle and a 100mL single-necked bottle at 60°C overnight and then cool to room temperature. Weigh 60g of tri-n-butylammonium pyrophosphate and add it to the above 100mL single-necked bottle, and evacuate overnight with an oil pump to obtain pretreated tri-n-butylammonium pyrophosphate.

[0041] (1) Add 10 g of 2'-deoxyguanosine to the above 1000 mL three-necked flask, add 400 mL of trimethyl phosphate to dissolve and disperse, add 30 mL of tri-n-butylamine, replace the atmosphere with nitrogen three times, and precool at -5°C for 30 min. Add 10 mL of phosphorus oxychloride dropwise using a constant pressure addition funnel, and continue the reaction at -5°C for 1.5 h after the addition is complete to obtain a reaction solution.

[0042] (2) Add 100 mL of anhydrous acetonitrile and 60 mL of tri-n-butylamine to the pretreated tri-n-butylammonium pyrophosphate, dissolve by ultrasonic dispersion, and precool at -10°C for 30 min. Then, add dropwise to the reaction solution obtained in step (1), and continue the reaction at -5°C for 15 min to obtain a deoxyribonucleoside triphosphate reaction solution dNTP-1.

[0043] 200 mL of 0.05 mol / L triethylamine carbonate icy water solution was added to the reaction solution obtained in step (1) of Preparation Example 1, and the mixture was quenched for 30 min. The mass percentage of the product in the reaction solution was 65% as determined by HPLC.

[0044] Preparation Example 2

[0045] This preparation example provides a crude nucleotide, specifically a deoxyribonucleoside triphosphate reaction solution dNTP-2, which differs from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with 2'-deoxycytidine of the same mass, the amount of trimethyl phosphate is adjusted to 300 mL, the amount of tri-n-butylamine is adjusted to 15 mL, the amount of phosphorus oxychloride is adjusted to 9.5 mL, and the reaction time is adjusted to 1 h; the amount of tri-n-butylamine in step (2) is adjusted to 65 mL, and the other conditions are the same as those in Example 1.

[0046] Preparation Example 3

[0047] This preparation example provides a crude nucleotide, specifically a deoxyribonucleoside triphosphate reaction solution dNTP-3, which differs from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with β-thymidine of the same mass, the amount of trimethyl phosphate is adjusted to 200 mL, the amount of tri-n-butylamine is adjusted to 20 mL, and the amount of phosphorus oxychloride is adjusted to 12 mL; the amount of tri-n-butylamine in step (2) is adjusted to 55 mL, and the other conditions are the same as in Example 1.

[0048] Preparation Example 4

[0049] This preparation example provides a crude nucleotide, specifically a deoxyribonucleoside triphosphate reaction solution dNTP-4, which differs from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with 2'-deoxyadenosine of the same mass, the amount of trimethyl phosphate is adjusted to 100 mL, the amount of tri-n-butylamine is adjusted to 30 mL, the amount of phosphorus oxychloride is adjusted to 9 mL, and the reaction time is adjusted to 1 h; the amount of tri-n-butylamine in step (2) is adjusted to 70 mL, the precooling temperature is adjusted to -20°C, and the other conditions are the same as those in Example 1.

[0050] Preparation Example 5

[0051] This preparation example provides a crude nucleotide, specifically a deoxyribonucleoside triphosphate reaction solution dNTP-5, which is different from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with the same mass of 2'-deoxyuridine, the amount of trimethyl phosphate is adjusted to 150 mL, 30 mL of tri-n-butylamine is replaced with 20 g of proton sponge (1,8-bis-(dimethylamino)-naphthalene), the amount of phosphorus oxychloride is adjusted to 4.6 mL, and the reaction time is adjusted to 0.5 h; the amount of tri-n-butylamine in step (2) is adjusted to 70 mL, and the other conditions are the same as in Example 1.

[0052] Preparation Example 6

[0053] This preparation example provides a crude nucleotide, specifically a dideoxyribonucleoside triphosphate reaction solution ddNTP-1, which differs from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with 2',3'-deoxycytidine of the same mass, the amount of trimethyl phosphate is adjusted to 500 mL, the amount of tri-n-butylamine is adjusted to 15 mL, the amount of phosphorus oxychloride is adjusted to 11 mL, and the reaction time is adjusted to 1.5 h; the amount of tri-n-butylamine in step (2) is adjusted to 65 mL, and the other conditions are the same as those in Example 1.

[0054] Preparation Example 7

[0055] This preparation example provides a crude nucleotide, specifically a dideoxyribonucleoside triphosphate reaction solution ddNTP-2, which differs from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with 2',3'-thymidine of the same mass, the amount of trimethyl phosphate is adjusted to 300 mL, the amount of tri-n-butylamine is adjusted to 15 mL, and the other conditions are the same as Example 1.

[0056] Preparation Example 8

[0057] This preparation example provides a crude nucleotide, specifically a dideoxyribonucleoside triphosphate reaction solution ddNTP-3, which differs from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with 2',3'-deoxyadenosine of the same mass, the amount of trimethyl phosphate is adjusted to 150 mL, the amount of phosphorus oxychloride is adjusted to 9 mL, and the reaction time is adjusted to 1 h; the amount of tri-n-butylamine in step (2) is adjusted to 65 mL, the precooling temperature is adjusted to -20°C, and the other conditions are the same as those in Example 1.

[0058] Preparation Example 9

[0059] This preparation example provides a crude nucleotide, specifically a dideoxyribonucleoside triphosphate reaction solution ddNTP-4, which differs from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with the same mass of 2',3'-deoxyuridine, the amount of trimethyl phosphate is adjusted to 300 mL, 30 mL of tri-n-butylamine is replaced with 15 g of proton sponge (1,8-bis-(dimethylamino)-naphthalene), the amount of phosphorus oxychloride is adjusted to 5 mL, and the reaction time is adjusted to 50 min; the amount of tri-n-butylamine in step (2) is adjusted to 50 mL, and the other conditions are the same as in Example 1.

[0060] Preparation Example 10

[0061] This preparation example provides a crude nucleotide, specifically a dideoxyribonucleoside triphosphate reaction solution ddNTP-5, which differs from Preparation Example 1 only in that 2'-deoxyguanosine in step (1) is replaced with 2',3'-deoxyuridine of the same mass, the amount of trimethyl phosphate is adjusted to 500 mL, and the amount of phosphorus oxychloride is adjusted to 11 mL; the amount of tri-n-butylamine in step (2) is adjusted to 50 mL, and the other conditions are the same as those in Example 1.

[0062] Preparation Example 11

[0063] This preparation example provides a crude nucleotide, specifically a deoxyribonucleoside triphosphate reaction solution containing an azide group, Cold dNTP-N3-1, which differs from Preparation Example 1 only in that the amount of tri-n-butylammonium pyrophosphate is adjusted to 50 g, 2'-deoxyguanosine in step (1) is replaced with the same mass of Cold dC-N3, the amount of trimethyl phosphate is adjusted to 200 mL, the amount of tri-n-butylamine is adjusted to 12 mL, the amount of phosphorus oxychloride is adjusted to 8 mL, and the reaction time is adjusted to 1.5 h; the amount of tri-n-butylamine in step (2) is adjusted to 65 mL, and the other conditions are the same as in Example 1.

[0064] Preparation Example 12

[0065] This preparation example provides a crude nucleotide, specifically a deoxyribonucleoside triphosphate reaction solution containing an azide group, Cold dNTP-N3-2, which is different from Preparation Example 1 only in that the amount of tri-n-butylammonium pyrophosphate is adjusted to 50 g, 2'-deoxyguanosine in step (1) is replaced with the same mass of Cold dT-N3, the amount of trimethyl phosphate is adjusted to 150 mL, the amount of tri-n-butylamine is adjusted to 12 mL, and the amount of phosphorus oxychloride is adjusted to 8 mL. Other conditions are the same as in Example 1.

[0066] Preparation Example 13

[0067] This preparation example provides a crude nucleotide, specifically a deoxyribonucleoside triphosphate reaction solution containing an azide group, Cold dNTP-N3-3, which differs from Preparation Example 1 only in that the amount of tri-n-butylammonium pyrophosphate is adjusted to 50 g, 2'-deoxyguanosine in step (1) is replaced by the same mass of Cold dA-N3, the amount of trimethyl phosphate is adjusted to 120 mL, the amount of tri-n-butylamine is adjusted to 16 mL, the amount of phosphorus oxychloride is adjusted to 7 mL, and the reaction time is adjusted to 1 h; the amount of tri-n-butylamine in step (2) is adjusted to 50 mL, the precooling temperature is -20°C, and the other conditions are the same as those in Example 1.

[0068] Preparation Example 14

[0069] This preparation example provides a crude nucleotide, specifically a deoxyribonucleoside triphosphate reaction solution containing an azide group, Cold dNTP-N3-4, which differs from Preparation Example 1 only in that the amount of tri-n-butylammonium pyrophosphate is adjusted to 50 g, 2'-deoxyguanosine in step (1) is replaced with the same mass of Cold dG-N3, the amount of trimethyl phosphate is adjusted to 300 mL, the amount of tri-n-butylamine is adjusted to 20 mL, and the amount of phosphorus oxychloride is adjusted to 8 mL; the amount of tri-n-butylamine in step (2) is adjusted to 40 mL, and the other conditions are the same as in Example 1.

[0070] Example 1

[0071] This embodiment provides a method for purifying nucleotide compounds, and the method for purifying nucleotide compounds comprises the following steps:

[0072] (1) Purification by weak anion exchange column chromatography: The deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 was diluted by 1-fold volume, and then purified by weak anion exchange column chromatography using a Santai column machine to collect the product fractions;

[0073] The packing material of the above-mentioned weak anion exchange column is DEAE packing material, brand SeplifeA25, purchased from Xi'an Lanxiao Technology;

[0074] The mobile phase for the weak anion exchange column chromatography purification includes mobile phase A and mobile phase B, wherein the mobile phase A is pure water, and the mobile phase B is a 1 mol / L triethylammonium carbonate aqueous solution (pH 8);

[0075] The column temperature of the above-mentioned weak anion exchange column is 25°C;

[0076] The elution mode of the above-mentioned weak anion exchange column chromatography purification is gradient elution, and the elution gradient conditions are shown in Table 1 below;

[0077] Table 1

[0078] Column Volume (CV) 0~3 3~10 10~15 15~20 20~25 Mobile phase A (V, %) 100 90 80 70 60 Mobile phase B (V, %) 0 10 20 30 40

[0079] The flow rate is 100 mL / min.

[0080] (2) The product fraction collected in step (1) was concentrated to 30 mL at 30° C. to obtain a nucleotide concentrated solution.

[0081] (3) The nucleotide concentrate obtained in step (2) was diluted to 50 mL by adding acetonitrile, and then slowly added dropwise to a saturated sodium iodide solution at 20° C., with a dropping rate of 5 g / min, to precipitate a solid, and then filtered and washed with acetone three times to obtain a pure product.

[0082] The above-mentioned saturated sodium iodide solution is a saturated sodium iodide solution under the conditions of 20° C. and 101.325 kPa.

[0083] Example 2

[0084] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the deoxyribonucleoside triphosphate reaction solution dNTP-2 of Preparation Example 2, and the elution gradient conditions are adjusted as shown in Table 2 below;

[0085] Table 2

[0086] Column Volume (CV) 0~5 5~10 10~18 18~23 23~30 Mobile phase A (V, %) 100 90 75 70 60 Mobile phase B (V, %) 0 10 25 30 40

[0087] Other conditions are the same as in Example 1.

[0088] Example 3

[0089] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the deoxyribonucleoside triphosphate reaction solution dNTP-3 of Preparation Example 3, and the elution gradient conditions are adjusted as shown in Table 3 below;

[0090] Table 3

[0091] Column Volume (CV) 0~5 5~10 10~18 18~23 23~30 Mobile phase A (V, %) 100 90 75 70 60 Mobile phase B (V, %) 0 10 25 30 40

[0092] The saturated sodium iodide solution in step (3) is replaced by a mixture of ethanol and a saturated sodium iodide solution. Based on the total mass of the saturated sodium iodide solution and the ethanol being 100%, the mass percentage of the saturated sodium iodide solution is 95%, and the mass percentage of the ethanol is 5%.

[0093] Other conditions are the same as in Example 1.

[0094] Example 4

[0095] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the deoxyribonucleoside triphosphate reaction solution dNTP-4 of Preparation Example 4.

[0096] Other conditions are the same as in Example 1.

[0097] Example 5

[0098] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the deoxyribonucleoside triphosphate reaction solution dNTP-5 of Preparation Example 5, and the elution gradient conditions are adjusted as shown in Table 4 below;

[0099] Table 4

[0100] Column Volume (CV) 0~3 3~10 10~13 13~20 20~30 Mobile phase A (V, %) 100 90 75 70 60 Mobile phase B (V, %) 0 10 25 30 40

[0101] The saturated sodium iodide solution in step (3) is replaced by a mixture of ethanol and a saturated sodium iodide solution. Taking the total mass of the saturated sodium iodide solution and the ethanol as 100%, the mass percentage of the saturated sodium iodide solution is 92%, and the mass percentage of ethanol is 8%.

[0102] Other conditions are the same as in Example 1.

[0103] Example 6

[0104] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the dideoxyribonucleoside triphosphate reaction solution ddNTP-1 of Preparation Example 6, and the elution gradient conditions are adjusted as shown in Table 5 below;

[0105] Table 5

[0106] Column Volume (CV) 0~5 5~10 10~18 18~23 23~30 Mobile phase A (V, %) 100 90 75 70 60 Mobile phase B (V, %) 0 10 25 30 40

[0107] Other conditions are the same as in Example 1.

[0108] Example 7

[0109] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the dideoxyribonucleoside triphosphate reaction solution ddNTP-2 of Preparation Example 7, and the elution gradient conditions are adjusted as shown in Table 6 below;

[0110] Table 6

[0111] Column Volume (CV) 0~5 5~10 10~18 18~23 23~30 Mobile phase A (V, %) 100 90 75 70 60 Mobile phase B (V, %) 0 10 25 30 40

[0112] The saturated sodium iodide solution in step (3) is replaced by a mixture of ethanol and a saturated sodium iodide solution. Based on the total mass of the saturated sodium iodide solution and the ethanol being 100%, the mass percentage of the saturated sodium iodide solution is 95%, and the mass percentage of the ethanol is 5%.

[0113] Other conditions are the same as in Example 1.

[0114] Example 8

[0115] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the dideoxyribonucleoside triphosphate reaction solution ddNTP-3 of Preparation Example 8.

[0116] Other conditions are the same as in Example 1.

[0117] Example 9

[0118] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the dideoxyribonucleoside triphosphate reaction solution ddNTP-4 of Preparation Example 9, and the elution gradient conditions are adjusted as shown in Table 7 below;

[0119] Table 7

[0120] Column Volume (CV) 0~3 3~10 10~13 13~20 20~30 Mobile phase A (V, %) 100 90 75 70 60 Mobile phase B (V, %) 0 10 25 30 40

[0121] The saturated sodium iodide solution in step (3) is replaced by a mixture of ethanol and a saturated sodium iodide solution. Taking the total mass of the saturated sodium iodide solution and the ethanol as 100%, the mass percentage of the saturated sodium iodide solution is 92%, and the mass percentage of ethanol is 8%.

[0122] Other conditions are the same as in Example 1.

[0123] Example 10

[0124] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the dideoxyribonucleoside triphosphate reaction solution ddNTP-10 of Preparation Example 8.

[0125] Other conditions are the same as in Example 1.

[0126] Embodiment 11

[0127] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the azide-containing deoxyribonucleoside triphosphate reaction solution Cold dNTP-N3-1 of Preparation Example 11, and the elution gradient conditions are adjusted as shown in Table 8 below;

[0128] Table 8

[0129]

[0130] The saturated sodium iodide solution in step (3) is replaced by a mixture of acetonitrile and a saturated sodium iodide solution, wherein the mass percentage of the saturated sodium iodide solution is 95%, and the mass percentage of the acetonitrile is 5%, based on the total mass of the saturated sodium iodide solution and the acetonitrile being 100%.

[0131] Other conditions are the same as in Example 1.

[0132] Example 12

[0133] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the azide-containing deoxyribonucleoside triphosphate reaction solution Cold dNTP-N3-2 of Preparation Example 12, and the elution gradient conditions are adjusted as shown in Table 9 below;

[0134] Table 9

[0135]

[0136]

[0137] The saturated sodium iodide solution in step (3) is replaced by a mixture of acetonitrile and a saturated sodium iodide solution, wherein the mass percentage of the saturated sodium iodide solution is 90%, and the mass percentage of the acetonitrile is 10%, based on the total mass of the saturated sodium iodide solution and the acetonitrile being 100%.

[0138] Other conditions are the same as in Example 1.

[0139] Embodiment 13

[0140] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the azide-containing deoxyribonucleoside triphosphate reaction solution Cold dNTP-N3-3 of Preparation Example 13, and the elution gradient conditions are adjusted as shown in Table 10 below;

[0141] Table 10

[0142]

[0143] The saturated sodium iodide solution in step (3) is replaced by a mixture of acetonitrile and a saturated sodium iodide solution, wherein the mass percentage of the saturated sodium iodide solution is 95%, and the mass percentage of the acetonitrile is 5%, based on the total mass of the saturated sodium iodide solution and the acetonitrile being 100%.

[0144] Other conditions are the same as in Example 1.

[0145] Embodiment 14

[0146] This example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that the deoxyribonucleoside triphosphate reaction solution dNTP-1 provided in Preparation Example 1 is replaced with the azide-containing deoxyribonucleoside triphosphate reaction solution Cold dNTP-N3-4 of Preparation Example 14, and the elution gradient conditions are adjusted as shown in Table 11 below;

[0147] Table 11

[0148]

[0149] The saturated sodium iodide solution in step (3) is replaced by a mixture of acetonitrile and a saturated sodium iodide solution, wherein the mass percentage of the saturated sodium iodide solution is 90%, and the mass percentage of the acetonitrile is 10%, based on the total mass of the saturated sodium iodide solution and the acetonitrile being 100%.

[0150] Other conditions are the same as in Example 1.

[0151] Comparative Example 1

[0152] This comparative example provides a method for purifying nucleotide compounds, which differs from Example 1 only in that: step (3) is adjusted to dilute the nucleotide concentrate obtained in step (2) to 50 mL with acetonitrile, and then purify by reverse phase column chromatography, and the collected product fractions are combined and concentrated to 30 mL at 30° C., pre-frozen at -80° C., and then freeze-dried to obtain a pure product.

[0153] The preparation equipment for the above-mentioned reverse phase column chromatography purification is a medium-pressure preparative liquid chromatography provided by Ruihe Technology, and the model of the reverse phase column is ArtChromWP C1810μ.

[0154] The eluents of the reverse phase column are chromatographic grade acetonitrile and 50 mmol / L triethylammonium carbonate aqueous solution.

[0155] The nucleotide concentrates and pure products prepared in the examples and comparative examples were subjected to the following tests.

[0156] (1) Purity after purification by weak anion exchange column chromatography: The nucleotide concentrate obtained in step (2) was pre-frozen at -80°C, then freeze-dried, and the purity of the product was detected by HPLC.

[0157] (2) Product purity: The purity of the pure product obtained in step (3) was tested by HPLC.

[0158] (3) Production cycle: The time required to convert the crude nucleotide into the pure nucleotide in the examples and comparative examples was recorded respectively.

[0159] The test results are shown in Table 12.

[0160] Table 12

[0161]

[0162] From the contents of Table 1, it can be seen that the purity of the pure product obtained by the purification method of nucleotide compounds provided in Examples 1-14 can reach 99%, the production cycle is 4 days, the purity is high, and the production cycle is short. By comparing Example 1 with Comparative Example 1, it can be seen that the present application uses weak anion exchange column chromatography for purification and precipitation of crystals to obtain a pure product with a purity of 99%, a production cycle of 4 days, and the purification process does not require reverse phase preparation equipment, the product production cycle is shorter, and the cost is lower.

[0163] The applicant declares that the present invention illustrates a method for purifying a nucleotide compound of the present invention through the above-mentioned embodiment, but the present invention is not limited to the above-mentioned embodiment, that is, it does not mean that the present invention must rely on the above-mentioned embodiment to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A method for purifying nucleotide compounds, characterized in that: The method for purifying nucleotide compounds comprises the following steps: purifying the crude nucleotide product by weak anion exchange column chromatography, mixing with a saturated sodium iodide solution to precipitate crystals, and obtaining a pure product.

2. The method for purifying nucleotide compounds according to claim 1, characterized in that: The weak anion exchange column chromatography purification further includes a concentration step; Preferably, the filler of the weak anion exchange column is DEAE filler.

3. The method for purifying nucleotide compounds according to claim 1 or 2, characterized in that: The mobile phase for the weak anion exchange column chromatography purification includes mobile phase A and mobile phase B, wherein the mobile phase A is pure water and the mobile phase B is a triethylammonium carbonate aqueous solution.

4. The method for purifying nucleotide compounds according to claim 3, characterized in that: The concentration of the triethylammonium carbonate aqueous solution is 0.5-2 mol / L; Preferably, the pH of the triethylammonium carbonate aqueous solution is 7-8.

5. The method for purifying nucleotide compounds according to any one of claims 1 to 4, characterized in that: The elution mode of the weak anion exchange column chromatography purification is gradient elution with a flow rate of 40 to 120 mL / min.

6. The method for purifying nucleotide compounds according to any one of claims 1 to 5, characterized in that: The solvent of the saturated sodium iodide solution is acetone.

7. The method for purifying nucleotide compounds according to any one of claims 1 to 6, characterized in that: The temperature of the precipitated crystals is 10-35°C.

8. The method for purifying nucleotide compounds according to any one of claims 1 to 7, characterized in that: The mixing also includes mixing with ethanol or acetonitrile; Preferably, based on the total mass of the saturated sodium iodide solution and ethanol or acetonitrile being 100%, the mass percentage of the saturated sodium iodide solution is 90% to 100%, and the mass percentage of ethanol or acetonitrile is 0 to 10%.

9. The method for purifying nucleotide compounds according to any one of claims 1 to 8, characterized in that: The method further comprises the steps of filtering and washing with acetone after the crystals are precipitated.

10. The method for purifying nucleotide compounds according to any one of claims 1 to 9, characterized in that: The purification method of the nucleotide compound specifically comprises the following steps: purifying the crude nucleotide product by weak anion exchange column chromatography, concentrating, mixing with a saturated sodium iodide solution and optionally ethanol or acetonitrile to precipitate crystals, filtering, and washing with acetone to obtain a pure product; The filler of the weak anion exchange column is DEAE filler, the mobile phase of the weak anion exchange column chromatography purification includes mobile phase A and mobile phase B, the mobile phase A is pure water, the mobile phase B is a triethylammonium carbonate aqueous solution with a concentration of 0.5 to 2 mol / L, and the elution mode of the weak anion exchange column chromatography purification is gradient elution with a flow rate of 40 to 120 mL / min; Taking the total mass of the saturated sodium iodide solution and ethanol or acetonitrile as 100%, the mass percentage of the saturated sodium iodide solution is 90% to 100% and the mass percentage of ethanol is 0 to 10%.